Illumina, Inc.
NASDAQ:ILMNMedical - Diagnostics & Research
+$1.95 today
- Market cap
- $31.75B
- Beta
- 1.49
- P/E (TTM)
- 28.9
- EPS (TTM)
- $5.58
Volume 1.63M
Average 1.65M
ILMN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Illumina, Inc.NASDAQ: ILMN
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA declines year over year
Q2 FY2026 EBITDA of $330M fell 17.3% year over year, ahead of the -23.6% change in trailing-twelve-month EBITDA. Sequentially, it rose 32.0% from the prior quarter.
Context
- EBITDA amounted to 33.6% of revenue in FY2025, up 17.0 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 14 analysts of $1.25B (-14.1%) for the fiscal year ending Dec 2026, a slowdown from the +301.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $330M+32.0% QoQ
- Last fiscal yearDec 2025
- $1.46B+301.0% YoY
- LTMJun 2026
- $1.36B-23.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -17.3% | -5.2% | +12.1 pp |
| 1 year | +301.0% | -14.1% | -315.1 pp |
| 3-year CAGR | — | +1.4% | — |
| 5-year CAGR | +4.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 1.46B USD
- Year-over-year change
- +301.0%
- 4-year CAGR
- +5.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 1.46B | +301.0% |
| FY2024 | 2024-12-29 | (725M) | -19.2% |
| FY2023 | 2023-12-31 | (608M) | +84.5% |
| FY2022 | 2023-01-01 | (3.92B) | -427.4% |
| FY2021 | 2022-01-02 | 1.2B | — |
EBITDA vs competitors
How ILMN compares with its peers on the latest reported figures
- ILMN's LTM Jun 2026 EBITDA of $1.36B is the highest of the 11 companies compared; the peer median is -$80.98M.
- Its year-over-year change of -23.6% is the 7th highest of 11, against a peer median of -0.5%.
- EBITDA amounts to 30.3% of revenue for ILMN, versus a peer median of 25.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.36B | -23.6% | — | 30.3% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $50.25M | +362.6% | — | 12.6% |
| LTM Sep 2026 | $37.56M | +221.9% | — | 6.1% | |
| LTM Jun 2026 | $12.89M | +145.3% | — | 1.7% | |
| LTM Mar 2026 | -$66.08M | -31.0% | — | 81.4% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | -$76.43M | -374.1% | — | 16.8% |
| LTM Mar 2026 | -$85.53M | -16.7% | — | 132.6% | |
| LTM Mar 2026 | -$106.6M | +54.1% | — | 66.6% | |
| LTM Jun 2026 | -$178.71M | +15.6% | — | 6.6% | |
| LTM Mar 2026 | -$334.2M | -423.0% | — | 40.3% | |
| LTM Sep 2026 | -$441.45M | -24.7% | — | 34.5% | |
| Peer median (excluding ILMN) | -$80.98M | -0.5% | — | 25.7% | |
Competitors are the stored peer set for ILMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.53B | 4.58B | 4.5B | 4.37B | 4.34B |
| Cost of Revenue | 1.37B | 1.61B | 1.76B | 1.51B | 1.45B |
| Gross Profit | 3.15B | 2.97B | 2.74B | 2.86B | 2.89B |
| Gross Margin | 69.7% | 64.8% | 60.9% | 65.4% | 66.7% |
| Research & Development | 1.19B | 1.32B | 1.35B | 1.17B | 951M |
| Selling, General & Admin | 2.09B | 1.3B | 1.61B | 1.09B | 1.08B |
| Operating Expenses | 3.28B | 7.15B | 3.81B | 3.69B | 2.03B |
| Depreciation & Amortization | 251M | 394M | 432M | 354M | 270M |
| EBITDA | 1.2B | (3.92B) | (608M) | (725M) | 1.46B |
| EBITDA Margin | 26.4% | -85.4% | -13.5% | -16.6% | 33.6% |
| Operating Income | (123M) | (4.18B) | (1.07B) | (833M) | 864M |
| Operating Margin | -2.7% | -91.2% | -23.7% | -19.1% | 19.9% |
| Interest Income | 0 | 11M | 58M | 46M | 40M |
| Interest Expense | 61M | 26M | 77M | 100M | 101M |
| Other Income / Expenses | 1.01B | (157M) | (48M) | (346M) | 222M |
| Income Before Tax | 884M | (4.34B) | (1.12B) | (1.18B) | 1.09B |
| Pre-Tax Margin | 19.5% | -94.6% | -24.8% | -27.0% | 25.0% |
| Income Tax Expense | 122M | 68M | 44M | 44M | 236M |
| Net Income | 762M | (4.4B) | (1.16B) | (1.22B) | 850M |
| Net Margin | 16.8% | -96.1% | -25.8% | -28.0% | 19.6% |
| EPS (Basic) | 5.08 | (28.05) | (7.35) | (7.69) | 5.48 |
| EPS (Diluted) | 5.05 | (28.05) | (7.35) | (7.69) | 5.45 |
| Weighted Avg Shares | 150M | 157M | 158M | 159M | 155M |
| Weighted Avg Shares (Diluted) | 151M | 157M | 158M | 159M | 156M |
Illumina, Inc.
NASDAQ:ILMN
Intrinsic Alpha fair value
Locked
Current Price
$210.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.